Skip to main content
. 2022 Jul 5;14(13):3280. doi: 10.3390/cancers14133280

Figure 5.

Figure 5

Hsa_circ_0072309 shows a promising potential as a biomarker of TNBC. (A) Validation of of hsa_circ_0072309, circ_0004365, circ_0006677, circ_0008599, circ_0009043, and circ_0000479 in two new sample sets: FFPE and frozen tissue (left and right panels, respectively) of TNBC patients (n = 6 and n = 10, respectively) and patients without cancer (n = 17 and n = 7, respectively. NC = non-cancer). p-values shown are from a Student’s t-test. Expression levels were calculated using the Comparative Ct method and ACTB and PUM1 were used as reference genes for frozen and ffpe tissues, respectively; (B) ROC curves of hsa_circ_0072309 in FFPE (bright red) and frozen tissue (dark red) samples showing an Area Under the Curve (AUC) with at least 0.78, indicating that this circRNA has good ability in discriminating TNBC from non-cancer patients; (C) Reactome enrichment of the RBPs with more than one binding site in hsa_circ_0072309 showing that this circRNA is acting in many cancer-related pathways, such as “Regulation of PTEN translation” and “Regulation of RUNX1 Expression and activity”.